Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-11-13
2000-11-28
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514336, 514345, 514346, 514354, 514357, 5462681, 546290, 546291, 546304, 546314, 546334, 546336, 546339, A61K 3144, C07D21302, A61P 1100, A61P 3700
Patent
active
06153630&
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
Asthma is a complex disease involving the concerted actions of multiple inflammatory and immune cells, spasmogens, inflammatory mediators, cytokines and growth factors. In recent practice there have been four major classes of compounds used in the treatment of asthma, namely bronchodilators (e.g., .beta.-adrenoceptor agonists), anti-inflammatory agents (e.g., corticosteroids), prophylactic anti-allergic agents (e.g., cromolyn sodium) and xanthines (e.g., theophylline) which appear to possess both bronchodilating and anti-inflammatory activity.
Theophylline has been a preferred drug of first choice in the treatment of asthma. Although it has been touted for its direct bronchodilatory action, theophylline's therapeutic value is now believed to also stem from anti-inflammatory activity. Its mechanism of action remains unclear. However, it is believed that several of its cellular activities are important in its activity as an anti-asthmatic, including cyclic nucleotide phosphodiesterase inhibition, adenosine receptor antagonism, stimulation of catecholamine release, and its ability to increase the number and activity of suppressor T-lymphocytes. While all of these actually may contribute to its activity, only PDE inhibition may account for both the anti-inflammatory and bronchodilatory components. However, theophylline is known to have a narrow therapeutic index, and a wide range of untoward side effects which are considered problematic.
Of the activities mentioned above, theophylline's activity in inhibiting cyclic nucleotide phosphodiesterase has received considerable attention recently. Cyclic nucleotide phosphodiesterases (PDEs) have received considerable attention as molecular targets for anti-asthmatic agents. Cyclic 3',5'-adenosine monophosphate (cAMP) and cyclic 3',5'-guanosine monophosphate (cGMP) are known second messengers that mediate the functional responses of cells to a multitude of hormones, neurotransmitters and autocoids. At least two therapeutically important effects could result from phosphodiesterase inhibition, and the consequent rise in intracellular adenosine 3',5'-monophosphate (cAMP) or guanosine 3',5'-monophosphate (cGMP)in key cells in the pathophysiology of asthma. These are smooth muscle relaxation (resulting in bronchodilation) and anti-inflammatory activity.
It has become known that there are multiple, distinct PDE isoenzymes which differ in their cellular distribution. A variety of inhibitors possessing a marked degree of selectivity for one isoenzyme or the other have been synthesized.
The structure-activity relationships (SAR) of isozyme-selective inhibitors has been discussed in detail, e.g., in the article of Theodore J. Torphy, et al., "Novel Phosphodiesterase Inhibitors For The Therapy Of Asthma", Drug News & Prospectives, 6(4) May 1993, pages 203-214. The PDE enzymes can be grouped into five families according to their specificity toward hydrolysis of cAMP or cGMP, their sensitivity to regulation by calcium, calmodulin or cGMP, and their selective inhibition by various compounds. PDE I is stimulated by Ca.sup.2+ /calmodulin. PDE II is cGMP-stimulated, and is found in the heart and adrenals. PDE III is cGMP-inhibited, and inhibition of this enzyme creates positive inotropic activity. PDE IV is cAMP specific, and its inhibition causes airway relaxation, anti-inflammatory and anti-depressant activity. PDE V appears to be important in regulating CGMP content in vascular smooth muscle, and therefore PDE V inhibitors may have cardiovascular activity.
While there are compounds derived from numerous structure activity relationship studies which provide PDE III inhibition, the number of structural classes of PDE IV inhibitors is relatively limited. Analogues of rolipram, which has the following structural formula: ##STR1## and of RO-20-1724, which has the following structural formula: ##STR2## have been studied.
Rolipram, which was initially studied because of its activity as an antidepressant has been shown to selectively inhibit the PDE IV enzyme an
REFERENCES:
patent: 2320654 (1943-06-01), Riester
patent: 2691654 (1954-10-01), Hitchings
patent: 2844577 (1958-07-01), Acker
patent: 2903455 (1959-09-01), Strong et al.
patent: 2956998 (1960-10-01), Baizer
patent: 2957875 (1960-10-01), Lyttle et al.
patent: 2966488 (1960-12-01), Shive et al.
patent: 3079378 (1963-02-01), Schroeder
patent: 3129225 (1964-04-01), Shapiro
patent: 3135753 (1964-06-01), Hitchings
patent: 3136771 (1964-06-01), Liechti et al.
patent: 3215696 (1965-11-01), Denayer
patent: 3225046 (1965-12-01), Zwahlen
patent: 3262929 (1966-07-01), Okubu et al.
patent: 3470164 (1969-09-01), Takamatsu
patent: 3491091 (1970-01-01), Berger
patent: 3491106 (1970-01-01), Freyermuth
patent: 3494919 (1970-02-01), Collins et al.
patent: 3516997 (1970-06-01), Takano et al.
patent: 3541100 (1970-11-01), Ramiriz et al.
patent: 3551554 (1970-12-01), Herschler
patent: 3574218 (1971-04-01), Hideg et al.
patent: 3586670 (1971-06-01), Brenneisen
patent: 3590029 (1971-06-01), Koch
patent: 3626018 (1971-12-01), Taylor
patent: 3636039 (1972-01-01), Gruenman et al.
patent: 3647812 (1972-03-01), Smith
patent: 3658799 (1972-04-01), Eardley
patent: 3666769 (1972-05-01), Jones
patent: 3669979 (1972-06-01), Freyermuth
patent: 3674781 (1972-07-01), Schinzel et al.
patent: 3681328 (1972-08-01), Kurita
patent: 3686238 (1972-08-01), Zaffaroni
patent: 3706834 (1972-12-01), Scheilenbaum et al.
patent: 3923833 (1975-12-01), Gruenmann et al.
patent: 3962452 (1976-06-01), Evans et al.
patent: 4020165 (1977-04-01), Hubbard
patent: 4025636 (1977-05-01), Dunwell et al.
patent: 4025637 (1977-05-01), Dunwell
patent: 4107306 (1978-08-01), Voorhees
patent: 4146721 (1979-03-01), Rainer
patent: 4167628 (1979-09-01), Kormany
patent: 4241168 (1980-12-01), Arai
patent: 4308278 (1981-12-01), Schneider et al.
patent: 4361699 (1982-11-01), Rasmusson et al.
patent: 4416892 (1983-11-01), Dawson
patent: 4495195 (1985-01-01), Beck et al.
patent: 4652654 (1987-03-01), Verga et al.
patent: 4684656 (1987-08-01), Atwal
patent: 4684728 (1987-08-01), Mohring
patent: 4710503 (1987-12-01), Hofer
patent: 4732978 (1988-03-01), Kreft et al.
patent: 4757124 (1988-07-01), Koyanagi
patent: 4770990 (1988-09-01), Nakamura
patent: 4803216 (1989-02-01), Appleton et al.
patent: 4810719 (1989-03-01), Appleton et al.
patent: 4826868 (1989-05-01), Wachter et al.
patent: 4831152 (1989-05-01), Itoh et al.
patent: 4851321 (1989-07-01), Takagi
patent: 4868183 (1989-09-01), Kanai et al.
patent: 4910211 (1990-03-01), Imamura et al.
patent: 4918074 (1990-04-01), Tsuda et al.
patent: 4925847 (1990-05-01), Hofer
patent: 4965169 (1990-10-01), Hirano
patent: 4981857 (1991-01-01), Daluge
patent: 4994363 (1991-02-01), Koya et al.
patent: 5047411 (1991-09-01), Takasugi et al.
patent: 5068236 (1991-11-01), Suzuki et al.
patent: 5098464 (1992-03-01), Barton et al.
patent: 5114835 (1992-05-01), Sakaoue
patent: 5116717 (1992-05-01), Matsushita
patent: 5117830 (1992-06-01), McAfee et al.
patent: 5139921 (1992-08-01), Takagi et al.
patent: 5190942 (1993-03-01), Poss
patent: 5191084 (1993-03-01), Bagli et al.
patent: 5206255 (1993-04-01), Ubasawa et al.
patent: 5264589 (1993-11-01), Corey
patent: 5288896 (1994-02-01), Capiris et al.
patent: 5322847 (1994-06-01), Marfat et al.
patent: 5342835 (1994-08-01), Pepin et al.
patent: 5434150 (1995-07-01), Austel et al.
patent: 5436258 (1995-07-01), Blake et al.
patent: 5449686 (1995-09-01), Christensen, IV et al.
patent: 5451596 (1995-09-01), Ullrich
patent: 5496853 (1996-03-01), Shiota et al.
patent: 5602157 (1997-02-01), Christensen, IV
patent: 5602173 (1997-02-01), Christensen, IV
patent: 5889014 (1999-03-01), Cavalla et al.
Katritzky et al., Heterocyclic Chemistry, John Wiley & Sons, Inc., pp. 247-253, 1960.
Grant et al., Grant and Hackh's Chemical Dictionary, McGraw-Hill Book Company, p. 282, 1987.
M.J. Ashton et al., Selective Type IV Phosphodiesterase Inhibitors As Antiasthmatic Agents. The Syntheses and Biological Activities of 3-(Cyclopentyloxy)-4-methoxybenzamides and Analogues, 1994, Journ
Cavalla David J.
Chasin Mark
Dolby Lloyd
Coleman Brenda
Euro-Celtique S.A.
Shah Mukund J.
LandOfFree
Phenylpyridyl compounds for inhibiting phosphodiesterase IV and does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phenylpyridyl compounds for inhibiting phosphodiesterase IV and , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phenylpyridyl compounds for inhibiting phosphodiesterase IV and will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1726219